A randomized cross-over study comparing pharmacodynamic and metabolic variables of a new combiphasic and a well-established triphasic oral contraceptive

European Journal of Contraception and Reproductive Health Care

Volumn 2, Issue 3, 1997, Pages 173-180

  Van Den Ende, A ^a   Geurts, T B P ^b   Kloosterboer, H J ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NV ORGANON   (Netherlands)

Author keywords

Combiphasic; Desogestrel; Levonorgestrel; Oral contraceptive; Pharmacodynamics; Triphasic

Indexed keywords

ANTITHROMBIN III; CARRIER PROTEIN; DESOGESTREL; ESTRADIOL; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE DERIVATIVE;

ARTICLE; BLOOD; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LIPID METABOLISM; METABOLISM; OVULATION; RANDOMIZED CONTROLLED TRIAL;

ANTITHROMBIN III; CARBOHYDRATE METABOLISM; CARRIER PROTEINS; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DESOGESTREL; ESTRADIOL; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL-NORGESTREL COMBINATION; FEMALE; HUMANS; LIPID METABOLISM; OVULATION; PROGESTERONE; PROGESTERONE CONGENERS;

EID: 0031217021     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189709167473     Document Type: Article

References (48)

1. Dieben TOM, van Beek A, Coelingh Bennink HJT. Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Arzneimittelforschung 1991; 41: 996-8
2. Dieben TOM, op ten Berg MT, Coelingh Bennink HJT. Cycle control and side effects of a new combiphasic oral contraceptive regimen. Arzneimittelforschung 1994; 44: 877-9
3. Oddens BJ, Arnolds HT, van Maris MGM, van Lunsen HW. The dynamics of oral contraceptive use in the Netherlands 1990-1993. Adv Contracept 1994; 10: 167-74
4. Dieben TOM, Vromans L, Theeuwes A, Coelingh Bennink HJT. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994; 50: 373-82
5. Falsetti L. Acne treatment with a new estroprogestinic biphasic combination containing desogestrel. Acta Eur Fertil 1991; 22: 283-6
6. Volpe A, Silferi M, Mauri A, et al. Efficacy on hyperandrogenism and safety of a new oral contraceptive biphasic formulation containing desogestrel. Eur J Obstet Gynecol Reprod Biol 1994; 53: 205-9
7. Hesse R, Tritschler W, Castelfranchi G, Bablok W. Antithrombin III: Referenzwerte mit einem chromogenen Substrat (Cromozym TH). Blut 1981; 42: 227-34
8. Barthelmai W, Czok R. Enzymatische Bestimmung der Glucose in Blut, Liquor und Harn. Klin Wochenschr 1962; 40: 585-9
9. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-6
10. Kloosterboer HJ, Bruining GJ, Lund L, et al. Serum glycosylated proteins as a measure of carbohydrate metabolism in OC users. In Harrison R, Bonnar J, Thompson W, eds. Trends in Oral Contraception. Lancaster: MTP Press, 1983; 9-15
11. Schosinski KH, Lehman HP, Beller MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of O-dianisidine dihydrochloride. Clin Chem 1974; 20: 1556-63
12. Schiller HS, Petra PH. A filter assay for the corticosteroid binding globulin of human serum. J Steroid Biochem 1976; 7: 55-9
13. Bergink EW, Holma P, Pyörälä T. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding. Scand J Clin Lab Invest 1981; 41: 663-8
14. Trinder P. Simple turbidimetric method for the determination of serum cholesterol. Ann Clin Biochem 1969; 6 165-6
15. Eggstein H, Kreutz FH. Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. Klin Wochenschr 1966; 44: 262-7
16. Takayama M, Itoh S, Nagasaki T, Tamimizu I. A new enzymatic method for determination of serum choline-containing phospholipids. Clin Chem Acta 1977; 79: 93-8
17. Terpstra AHM, Woodward CJH, Sanchez-Muniz FJ. Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum. Anal Biochem 1981; 111: 149-57
18. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1978; 11: 583-95
19. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three methods. Clin Chem 1977; 23: 882-4
20. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
21. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979; 8: 7-20
22. Guillebaud J. The forgotten pill - and the paramount importance of the pill-free week. Br J Fam Plann 1987; 12(Suppl 4): 35-43
23. Kuhl H, Jung-Hoffmann C, Weber J, Boehm BO. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception 1993; 47: 55-68
24. Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: glucose, insulin, and growth hormone studies in one hundred and seventy women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol 1972; 114: 378-92
25. Spellacy WN, Buhi WC, Birk SA. The effects of two years of mestranol treatment on carbohydrate metabolism. Metabolism 1982; 31: 1006-8
26. Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1991; 74: 64-70
27. Gaspard U, Lefebre PJ. Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease. Am J Obstet Gynecol 1990; 163: 334-43
28. Brien TG. Human corticosteroid binding globulin. Clin Endocrinol 1981; 14: 193-212
29. Adlercreutz H, Eisalo A, Heino A, et al. Investigations on the effects of an oral contraceptive and its components on liver function, serum proteins, copper, ceruloplasmin and gamma-glutamyl peptidase in postmenopausal women. Scand J Gastroenterol 1968; 3: 273-84
30. Jung-Hoffmann C, Storch A, Kuhl H. Serum concentrations of ethinylestradiol, 3-keto-desogestrel, SHBG, CBG and gonadotropins during treatment with a biphasic oral contraceptive containing desogestrel. Horm Res 1992; 38: 184-9
31. Cullberg G, Dovré PA, Lindstedt G, Steffensen K. On the use of plasma proteins as indicators of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand 1982; (Suppl 111): 47-54
32. Liukko P, Erkkola R, Bergink EW. Progestagen-dependent effect on some plasma proteins during oral contraception. Gynecol Obstet Invest 1988; 25: 118-22
33. Lobl TJ. Androgen transport proteins: physical properties, hormonal regulation, and possible mechanism of TeBG and ABP action. Arch Androl 1981; 7: 133-51
34. Kloosterboer HJ, Vonk Noordegraaf CA, Turpijn EW. Selectivity in progesterone- and androgen-receptor binding of progestogens used in oral contraceptives. Contraception 1988; 38: 325-32
35. Mammen EF. Oral contraception and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142: 781-90
36. Kuhl H, März W, Jung-Hoffmann C, et al. Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: divergent changes in apolipoprotein B and E and transitory decrease in Lp(a) levels. Contraception 1993; 47: 69-83
37. Jacobs DR, Mebane IL, Bangdiwala SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131: 32-47
38. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987; 114: 413-19
39. Livshits G, Weisbort J, Meshulam N, Brunner D. Multivariate analysis of the twenty-year follow-up of the Donol-Tel Aviv Prospective Coronary Artery Disease Study and the usefulness of high density lipoprotein cholesterol percentage. Am J Cardiol 1989; 63: 676-81
40. Manninen V, Elo MO, Frick MH, et al. Lipoprotein alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J Am Med Assoc 1988; 260: 641-51
41. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98
42. Blankenhorn DH, Johnson RL, Nessim SA, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 1987; 257: 3233-40
43. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 432-7
44. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. J Am Med Assoc 1993; 269: 505-10
45. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinics' Program Follow-Up Study. Circulation 1987; 75: 1002-9
46. Lewis MA, Spitzer WO, Heinemann LA, et al. on behalf of the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Br Med J 1996; 312: 88-90
47. Jick H, Jick SS, Wald Myers M, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 1996; 347: 627-8
48. Consensus Development meeting. Metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990; 162: 1335-7